Devyser Diagnostics AB (publ) (STO: DVYSR)

Market Cap	2.20B
Revenue (ttm)	198.10M
Net Income (ttm)	-71.40M
Shares Out	16.51M
EPS (ttm)	-4.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,908
Open	132.00
Previous Close	132.00
Day's Range	131.50 - 135.00
52-Week Range	63.00 - 141.00
Beta	0.76
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2024

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) develops, manufactures, and sells diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as acce...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 118
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DVYSR

Financial Performance

In 2023, Devyser Diagnostics AB's revenue was 169.30 million, an increase of 33.73% compared to the previous year's 126.60 million. Losses were -53.60 million, 16.5% more than in 2022.